10-K: Allurion Technologies Reports 2023 Financial Results, Navigates Market Challenges

Allurion Technologies experienced a 17% year-over-year revenue decline in 2023, alongside a significant increase in net losses, as it continues to develop its weight loss platform.

Summary

• Allurion Technologies, a medical device company focused on weight loss, reported a revenue of $53.5 million in 2023, a 17% decrease compared to $64.2 million in 2022.
• The company's gross profit margin remained strong at 78% in 2023, slightly down from 79% in 2022.
• Net losses significantly increased to $80.6 million in 2023, compared to $37.7 million in 2022.
• The company attributes the revenue decline to a delay in closing the Business Combination, which led to decreased investment in certain markets and lower re-order rates.
• Operating expenses increased significantly, particularly in research and development, which rose by 63% to $27.7 million, and general and administrative expenses, which increased by 199% to $46.0 million.
• The company completed enrollment of 550 patients in its AUDACITY clinical trial in the United States, with results expected to support a premarket approval (PMA) submission to the FDA.
• Allurion has a broad portfolio of intellectual property, including 18 issued and 5 pending patents in the U.S. related to its Allurion Balloon.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant challenges in revenue and profitability, offset by progress in clinical trials and intellectual property. The financial results are concerning, but the company is taking steps to address these issues.

Positives

• The company maintains a strong gross profit margin of 78%.
• Allurion completed enrollment in its AUDACITY clinical trial, a key step towards FDA approval.
• The company has a broad intellectual property portfolio with 54 issued patents.
• The Allurion Program has treated over 130,000 patients in over 50 countries outside the U.S.

Negatives

• Allurion experienced a 17% decrease in revenue year-over-year.
• The company's net loss increased significantly to $80.6 million in 2023.
• Operating expenses, particularly in research and development and general and administrative, increased substantially.
• The company has a significant amount of debt, which may affect its ability to operate and secure additional financing.

Risks

• The company expects to incur losses for the foreseeable future and its ability to achieve profitability depends on the commercial success of the Allurion Balloon.
• There is no guarantee that the FDA or non-U.S. regulatory agencies will grant approval or clearance for the Allurion Balloon or other products.
• The weight loss and obesity management industries are highly competitive.
• The company depends on a limited number of single-source suppliers, making it vulnerable to supply shortages and price fluctuations.
• The company has a significant amount of debt, which may affect its ability to operate and secure additional financing.
• The company's share price may be volatile, and purchasers of its securities could incur substantial losses.

Future Outlook

The company expects continued geographic expansion to be a key driver of growth over the next three years and plans to expand the sale of the VCS in a Software as a Service (SaaS) model. Allurion also plans to leverage its proprietary product technology and research and development expertise to expand its current label, if approved, into adolescents and a lower BMI population.

Management Comments

• The company believes that its business-to-business-to-consumer (B2B2C) business model creates an economic benefit for all key stakeholders.
• The company believes that its platform addresses the limitations of current weight loss treatments, including poor patient and health care provider experience, complex safety profiles, poor economics, limited channels, and flawed go-to-market strategies.
• The company believes that the Allurion Program provides considerable advantages to patients and providers, including a consumer-centric, procedure-less technology with a favorable safety profile, an end-to-end weight management platform powered by AI and data, life-changing clinical outcomes that are fast yet durable, attractive economics for patients and providers, and a broad patent portfolio and proprietary manufacturing capabilities.

Industry Context

The announcement reflects the challenges and opportunities in the competitive weight loss and obesity management industry, where companies are striving to develop safer, more effective, and consumer-centric treatments. Allurion is competing with both medical device and pharmaceutical companies in this space.

Comparison to Industry Standards

• The document compares Allurion's serious adverse event (SAE) rate to that of ReShape Lifesciences, Inc. and Apollo Endosurgery, Inc., noting that Allurion has reported a lower device or procedure-related SAE rate.
• The document also compares the mean weight loss at 24 weeks in the ReShape Duo Balloon pivotal trial (14.3 pounds) to the average weight loss of Allurion patients (14% of total body weight or 30 pounds on average after just four months).
• The document notes that the ReShape Duo Balloon pivotal trial showed that the average treatment subject regained 40% of the weight loss at 48 weeks, resulting in a mean weight loss of 9.9 pounds at 48 weeks, while Allurion patients sustain 95% of their weight loss at one year.

Related Party Transactions

• The company entered into a lease agreement with a related party for office space in Paris, France.
• The company entered into consulting agreements with KKG Enterprises, LLC and Remus Group Management, LLC, which are related to a director of Allurion.
• The company entered into a corporate officer agreement with its Chief Commercial Officer and Benoit Chardon Consulting.
• The company entered into a termination agreement with its Chief Commercial Officer and Benoit Chardon Consulting.

Stakeholder Impact

• Shareholders may experience volatility in the share price and potential losses.
• Employees may be affected by restructuring plans and potential job losses.
• Customers may experience changes in product availability or service.
• Suppliers may be affected by changes in the company's financial condition or supply chain.
• Creditors may be concerned about the company's ability to repay its debt.

Next Steps

• The company plans to expand revenues in key existing markets.
• The company expects to launch the Allurion Program in new markets.
• The company aims to obtain FDA approval and enter the U.S. market.
• The company intends to expand the VCS to enhance the balloon experience and engage patients for a lifetime.
• The company plans to expand its label, advance its product pipeline, and strengthen its weight loss platform.
• The company may monetize its marketing funnel through partnership or acquisition.

Key Dates

Keywords

Allurion Balloon, weight loss, obesity, intragastric balloon, medical device, FDA approval, clinical trial, virtual care suite, revenue, net loss